OticPharma to Present at the 2016 JMP Securities Life Sciences Conference

IRVINE, Calif. and REHOVOT, Israel, July 17, 2016 /PRNewswire/ — OticPharma, Ltd., a privately-held specialty pharmaceutical organization centered on obtaining and developing innovative treatments for hearing, nose, and neck (ENT) problems, today declared that Gregory J. Flesher, CEO, will show in the JMP Securities Life Sciences Meeting on Tuesday, June 21, 2016 at 11:00 AM EDT in the St. Regis Ny.

About OticPharma

OticPharma is just a medical-phase pharmaceutical company concentrating on the purchase and improvement of ear, nose, and neck (ENT) items that recover health insurance and tackle unmet requirements in kids and adults.  the Business’s amazing foam engineering (OP-01) is being created for acute otitis externa (“swimmers ear”) and it is being investigated for that therapy of nasal and sinus conditions.  the Business’s amazing surfactant technologies (OP-02) is being created like a possible first-in-course, antibiotic-free therapy choice for severe, repeated, and persistent otitis media.

Buyer and Advertising Contact
Gita Ogawa
The Bass Team
Gogawa@troutgroup.com
Tel: +1 (646) 378-2949

Business Contact
Gregory J. Flesher
OticPharma, Ltd.
gflesher@oticpharma.com
Tel: +1 (949) 238-8090

Emblem – http://photos.prnewswire.com/prnh/20150902/263275LOGO

 

SUPPLY OticPharma, Ltd.

Leave a Reply

Your email address will not be published. Required fields are marked *